DHDH

Summary

DHDH (dihydrodiol dehydrogenase, HGNC:17887) is a protein-coding gene on chromosome 19q13.33, encoding Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase (Q9UQ10).

This gene encodes an enzyme that belongs to the family of dihydrodiol dehydrogenases, which exist in multiple forms in mammalian tissues and are involved in the metabolism of xenobiotics and sugars. These enzymes catalyze the NADP1-linked oxidation of transdihydrodiols of aromatic hydrocarbons to corresponding catechols. This enzyme is a dimeric dihydrodiol dehydrogenase, and it differs from monomeric dihydrodiol dehydrogenases in its high substrate specificity for trans-dihydrodiols of aromatic hydrocarbons in the oxidative direction.

Source: NCBI Gene 27294 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 79 total
• MANE Select transcript: NM_014475

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17887
Approved symbol	DHDH
Name	dihydrodiol dehydrogenase
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	HUM2DD
Ensembl gene	ENSG00000104808
Ensembl biotype	protein_coding
OMIM	606377
Entrez	27294

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay

ENST00000221403, ENST00000520557, ENST00000522614, ENST00000523250

RefSeq mRNA: 1 — MANE Select: NM_014475 NM_014475

CCDS: CCDS12741

Canonical transcript exons

ENST00000221403 — 7 exons

Exon	Start	End
ENSE00000718506	48935000	48935111
ENSE00000718513	48936032	48936195
ENSE00000718527	48942440	48942564
ENSE00001229678	48944824	48944969
ENSE00001229684	48933699	48933811
ENSE00003533086	48944357	48944507
ENSE00003544196	48939449	48939701

Expression profiles

Bgee: expression breadth ubiquitous, 156 present calls, max score 90.85.

FANTOM5 (CAGE): breadth broad, TPM avg 1.0548 / max 74.2322, expressed in 420 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
176883	1.0548	420

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney epithelium	UBERON:0004819	90.85	gold quality
ileal mucosa	UBERON:0000331	89.41	gold quality
jejunal mucosa	UBERON:0000399	89.17	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.05	gold quality
duodenum	UBERON:0002114	87.84	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.87	gold quality
adult mammalian kidney	UBERON:0000082	79.38	gold quality
jejunum	UBERON:0002115	78.04	gold quality
kidney	UBERON:0002113	75.72	gold quality
sperm	CL:0000019	73.94	gold quality
small intestine	UBERON:0002108	73.05	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.78	gold quality
amniotic fluid	UBERON:0000173	71.76	silver quality
cortex of kidney	UBERON:0001225	70.67	gold quality
buccal mucosa cell	CL:0002336	69.67	gold quality
prefrontal cortex	UBERON:0000451	69.61	gold quality
cerebellar hemisphere	UBERON:0002245	69.42	gold quality
renal medulla	UBERON:0000362	69.37	gold quality
cerebellar cortex	UBERON:0002129	69.29	gold quality
cerebellum	UBERON:0002037	68.78	gold quality
right hemisphere of cerebellum	UBERON:0014890	67.96	gold quality
cardia of stomach	UBERON:0001162	67.47	gold quality
spleen	UBERON:0002106	67.04	gold quality
Brodmann (1909) area 9	UBERON:0013540	66.85	gold quality
epithelial cell of pancreas	CL:0000083	66.81	gold quality
nucleus accumbens	UBERON:0001882	66.67	gold quality
right frontal lobe	UBERON:0002810	66.55	gold quality
pituitary gland	UBERON:0000007	66.35	gold quality
frontal cortex	UBERON:0001870	66.35	gold quality
vena cava	UBERON:0004087	66.16	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.07

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 5)

• Site-directed mutagenesis of conserved residues shows that Tyr-180 plays a critical role in the catalytic function of this enzyme, while His-79 is required in the coenzyme binding and chemical steps of the reaction. (PMID:11097839)
• Comparison of other mammalian homologs with the human enzyme shows that dimeric DDs constitute a novel protein family. (PMID:11306093)
• Survival was significantly better in gastric cancer patients with low DDH expression. (PMID:18600452)
• Possible association of both variants of the DHDH gene with familial Dupuytren’s disease, as over-representation of the rs2270941 and rs11666105 alterations was identified among 100 patients with a familial history. (PMID:23303836)
• Some genetical studies show also altered expression of the dehydrogenases ALDH2 and DHDH genes in patients with Dupuytren’s disease and with digestive tract malignancies related to alcohol abuse.(review) (PMID:24734329)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	dhdh.2	ENSDARG00000019081
danio_rerio	dhdh.1	ENSDARG00000028336
mus_musculus	Dhdh	ENSMUSG00000011382
rattus_norvegicus	Dhdh	ENSRNOG00000020883
drosophila_melanogaster	CG3597	FBGN0031417
drosophila_melanogaster	CG3609	FBGN0031418
drosophila_melanogaster	CG13280	FBGN0032609

Paralogs (3): BLVRA (ENSG00000106605), GFOD2 (ENSG00000141098), GFOD1 (ENSG00000145990)

Protein

Protein identifiers

Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase — Q9UQ10 (reviewed: Q9UQ10)

Alternative names: D-xylose 1-dehydrogenase, D-xylose-NADP dehydrogenase, Dimeric dihydrodiol dehydrogenase, Hum2DD

All UniProt accessions (4): E5RFE0, E5RGT8, Q9UQ10, H0YBU7

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Homodimer.

Tissue specificity. Small intestine.

Similarity. Belongs to the Gfo/Idh/MocA family.

RefSeq proteins (1): NP_055290* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000683	Gfo/Idh/MocA-like_OxRdtase_N	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR050984	Gfo/Idh/MocA_domain	Family
IPR055170	GFO_IDH_MocA-like_dom	Domain

Pfam: PF01408, PF22725

Catalyzed reactions (Rhea), 2 shown:

• (1R,2R)-1,2-dihydrobenzene-1,2-diol + NADP(+) = catechol + NADPH + H(+) (RHEA:16729)
• D-xylose + NADP(+) = D-xylono-1,5-lactone + NADPH + H(+) (RHEA:22000)

UniProt features (11 total): site 5, sequence variant 5, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UQ10-F1	98.19	0.99

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (5): 71 (may play an important role in coenzyme binding); 79 (may play an important role in coenzyme binding); 97 (may play an important role in coenzyme binding); 176 (may play an important role for the adaptation of the alcohol substrate into the binding site); 180 (may play an important role in catalytic activity)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 55 (showing top): GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS, GOBP_MONOSACCHARIDE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_CATABOLIC_PROCESS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS, GOBP_MONOSACCHARIDE_METABOLIC_PROCESS, GOBP_PENTOSE_METABOLIC_PROCESS, KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR, KEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED, ANDERSEN_CHOLANGIOCARCINOMA_CLASS2, ARNT2_TARGET_GENES, ATF6_TARGET_GENES

GO Biological Process (1): D-xylose catabolic process (GO:0042843)

GO Molecular Function (4): nucleotide binding (GO:0000166), trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (GO:0047115), D-xylose 1-dehydrogenase (NADP+) activity (GO:0047837), oxidoreductase activity (GO:0016491)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
pentose catabolic process	1
D-xylose metabolic process	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor	1
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	1
catalytic activity	1

Protein interactions and networks

STRING

1365 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DHDH	AKR1C4	P17516	925
DHDH	AKR1C1	P52896	913
DHDH	AKR1C2	P52895	907
DHDH	AKR1C3	P42330	899
DHDH	DHRS9	Q9BPW9	834
DHDH	H2BC21	Q16778	722
DHDH	B2M	P01884	576
DHDH	KLRD1	Q13241	576
DHDH	ENPEP	Q07075	550
DHDH	CD8A	P01732	540
DHDH	ITIH4	Q14624	529
DHDH	CD300A	Q9UGN4	473
DHDH	CD300LF	Q8TDQ1	472
DHDH	AKR1A1	P14550	464
DHDH	DDX53	Q86TM3	450

IntAct

3 interactions, top by confidence:

A	B	Type	Score
DHDH	ATRN	psi-mi:“MI:0914”(association)	0.530
DHDH	ZNF185	psi-mi:“MI:0914”(association)	0.350

BioGRID (46): CCDC12 (Affinity Capture-MS), TSC22D1 (Affinity Capture-MS), CBWD3 (Affinity Capture-MS), NFXL1 (Affinity Capture-MS), TUBB (Affinity Capture-MS), AP3M2 (Affinity Capture-MS), TUBA1C (Affinity Capture-MS), CDC42EP1 (Affinity Capture-MS), ICAM1 (Affinity Capture-MS), CCP110 (Affinity Capture-MS), CCDC47 (Affinity Capture-MS), MADD (Affinity Capture-MS), FAM91A1 (Affinity Capture-MS), ARHGEF4 (Affinity Capture-MS), HK2 (Affinity Capture-MS)

ESM2 similar proteins: D3ZDK7, E9Q3E1, O93539, O93541, O93542, O93543, O93545, O93546, P00325, P00328, P13439, P31754, P33571, P42122, P43353, P69080, P69081, P69082, P69085, P69086, P70473, P80338, P81600, P97849, Q08415, Q148L6, Q16773, Q1JPA0, Q3TY86, Q5R1W2, Q5R5J5, Q5RDY4, Q5TEU4, Q60714, Q642M9, Q64674, Q6DF30, Q6DKE0, Q6P1M0, Q7JK39

Diamond homologs: A0A024SMV2, A0R191, A4FDY3, A6WFC5, A9N564, B3TMR8, B5F3F4, C0ZWI9, D4GP30, F0M433, O13991, O32223, O42896, P40332, P46853, P49307, P77376, Q148L6, Q44258, Q54728, Q5R5J5, Q642M9, Q6DF30, Q6DKE0, Q7CV90, Q7JK39, Q88S38, Q8ZK57, Q92KZ3, Q9ALN5, Q9DBB8, Q9TQS6, Q9TV68, Q9TV69, Q9TV70, Q9UQ10, Q9UT60, Q9ZA33, A0A0F7VN41, A0JT53

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

862 predictions. Top by Δscore:

Variant	Effect	Δscore
19:48933807:ACCAG:A	donor_loss	1.0000
19:48933808:CCAGG:C	donor_loss	1.0000
19:48933809:CAGGT:C	donor_loss	1.0000
19:48933811:GG:G	donor_loss	1.0000
19:48933812:G:T	donor_loss	1.0000
19:48933837:G:GT	donor_gain	1.0000
19:48933837:G:T	donor_gain	1.0000
19:48934995:TCCA:T	acceptor_loss	1.0000
19:48934998:A:AC	acceptor_loss	1.0000
19:48934998:A:AG	acceptor_gain	1.0000
19:48934998:AG:A	acceptor_gain	1.0000
19:48934998:AGGT:A	acceptor_gain	1.0000
19:48934998:AGGTG:A	acceptor_gain	1.0000
19:48934999:G:A	acceptor_loss	1.0000
19:48934999:G:GT	acceptor_gain	1.0000
19:48934999:GG:G	acceptor_gain	1.0000
19:48934999:GGT:G	acceptor_gain	1.0000
19:48934999:GGTG:G	acceptor_gain	1.0000
19:48934999:GGTGG:G	acceptor_gain	1.0000
19:48935108:GTGG:G	donor_gain	1.0000
19:48935109:TGG:T	donor_gain	1.0000
19:48935110:GG:G	donor_gain	1.0000
19:48935110:GGG:G	donor_gain	1.0000
19:48935110:GGGT:G	donor_loss	1.0000
19:48935111:GG:G	donor_gain	1.0000
19:48935111:GGTG:G	donor_loss	1.0000
19:48935112:G:GG	donor_gain	1.0000
19:48935113:T:A	donor_loss	1.0000
19:48936027:CCTA:C	acceptor_loss	1.0000
19:48936028:CTA:C	acceptor_loss	1.0000

AlphaMissense

2171 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:48942505:A:C	S229R	0.984
19:48942507:C:A	S229R	0.984
19:48942507:C:G	S229R	0.984
19:48936116:A:T	E96V	0.982
19:48935042:T:C	F45L	0.978
19:48935044:T:A	F45L	0.978
19:48935044:T:G	F45L	0.978
19:48944835:A:C	S303R	0.975
19:48944837:T:A	S303R	0.975
19:48944837:T:G	S303R	0.975
19:48933734:T:A	W5R	0.971
19:48933734:T:C	W5R	0.971
19:48944447:T:C	F279L	0.967
19:48944449:T:A	F279L	0.967
19:48944449:T:G	F279L	0.967
19:48939542:T:C	F154L	0.966
19:48939544:T:A	F154L	0.966
19:48939544:T:G	F154L	0.966
19:48933770:T:C	F17L	0.965
19:48933772:C:A	F17L	0.965
19:48933772:C:G	F17L	0.965
19:48944476:G:C	E288D	0.965
19:48944476:G:T	E288D	0.965
19:48933736:G:C	W5C	0.956
19:48933736:G:T	W5C	0.956
19:48936117:G:C	E96D	0.954
19:48936117:G:T	E96D	0.954
19:48944414:T:C	F268L	0.950
19:48944416:C:A	F268L	0.950
19:48944416:C:G	F268L	0.950

dbSNP variants (sampled 300 via entrez): RS1000022331 (19:48932310 G>A), RS1000038394 (19:48940592 G>A), RS1000087336 (19:48940750 G>A), RS1000909338 (19:48935756 G>A), RS1001552289 (19:48941422 C>T), RS1001660744 (19:48936770 G>A), RS1001793559 (19:48945397 G>A,C), RS1001818986 (19:48931069 T>G), RS1002159577 (19:48939954 G>A), RS1002255275 (19:48945163 A>G), RS1002360808 (19:48935539 C>T), RS1002412360 (19:48945322 GAAA>G,GAA,GAAAA), RS1002675524 (19:48940424 T>A), RS1002702788 (19:48934126 G>A), RS1002763753 (19:48935257 C>T)

Disease associations

OMIM: gene MIM:606377 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	2
Silicon Dioxide	increases expression	2
Tobacco Smoke Pollution	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
propionaldehyde	increases expression	1
mesitylene	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
licochalcone B	increases expression	1
PCI 5002	increases expression, affects cotreatment	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Copper	affects binding, decreases expression	1
Disulfiram	affects binding, decreases expression	1
Hydrogen Peroxide	affects expression	1
Mustard Gas	increases expression	1
Silver	increases expression	1
Sodium Dodecyl Sulfate	increases expression	1
Thiram	increases expression	1
Valproic Acid	increases expression	1
Zinc	affects cotreatment, increases expression	1
Copper Sulfate	increases expression	1
Acrylamide	increases expression	1
Particulate Matter	increases abundance, increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_2106	M-07e	Cancer cell line	Female
CVCL_RM07	M-07e/TPO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer